Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

Black boxes: health warning or profit warning?

Martha Rosenberg
Meds
February 1, 2020
Share
Tweet
Share

“Boxed warnings” or “black boxes” are the strictest FDA label warnings. They appear on cigarettes, fluoroquinolones (for tendon rupture), Lamictal (for SJS and TEN), Accutane (birth defects), and other products with well-known risks.

The industry obviously dislikes black boxes since they reduce sales (though their lobbyists charge the boxes “confuse” and “unnecessarily alarm” patients).

So it was no surprise that when the FDA held a Joint Meeting of the Pediatric and Drug Safety and Risk Management Advisory Committees on September 27, 2019, to address growing reports of neuropsychiatric events from montelukast in pediatric patients there was a lot of talk about black boxes.

Montelukast, marketed as Singulair, is a leukotriene receptor antagonist used in asthma and allergy.

Singulair was Merck’s biggest seller when on patent, bringing in $3.3 billion in 2011 and named one of Kiplinger’s 15 all-time best-selling prescription drugs. Merck used Scholastic, the educational publishing group, and the American Academy of Pediatrics to help market it.

Testifying at the hearings were parents whose children had taken their own lives on the drug or experienced other severe harm.

The parents, from groups like Parents United for Pharmaceutical Safety and Accountability and the Montelukast Side Effects Support and Discussion Group, asserted that a black box warning would prevent future tragedies. The current montelukast label only warns against “neuropsychiatric events.”

Many safety signals

Fox 5 first reported neuropsychiatric events in late 2010 — parents seeing aggressive behavior, hostility, hallucinations, night-terrors, tremors, irritability, anxiety, depression, and even suicide in their children taking montelukast.

But red flags existed much earlier, especially regarding montelukast’s effect on children. In the late 1990s, FDA reviewers note in montelukast’s new drug approval documents note that infant monkey had to be euthanized and “may be more sensitive to the toxicity.”

In 1998, Peter Honig and John Jenkins of the FDA repeated the warning cautioning in the New England Journal of Medicine that adult studies of the montelukast “may not be predictive of the response,” in children.

In 2016, a Vigibase report found that suicidal behavior “and completed suicide appear to be more frequently reported than previously thought in practice.” In 2018, research in the Springer journal Drug Safety reported that “ten pharmacovigilance studies using different global databases detected the signals” of neuropsychiatric events.

Even the briefing documents released by the FDA for montelukast September hearings were something of a red flag. They acknowledge, for the first time, the drug’s action on the brain as a competitive antagonist of GPR17, not merely acting on the CysLT1 receptor as prescribing information portrays. The new information is relevant to the neuropsychiatric events under investigation, said parents at the hearings.

To add a black box to montelukast or not?

ADVERTISEMENT

Steven Meisel, PharmD, CPPS, Director of Medication Safety Fairview Health Services, and a FDA committee member agreed that a black box is necessary. The “FAERS data shows that between six and 800 neuropsychiatric events have been reported every year,” he said, and the 35 million montelukast prescriptions written a year tell “me that this drug is being prescribed in a cavalier manner.”

Christy Turer, an internist and a pediatrician on the committee, also recommended a black box. “In thinking about risk-benefit, I think the black box would send a message and would decrease prescribing,” she said. “We as a country, our physicians, our prescribers, we over-prescribe.”

But others on the FDA committee disagreed. Jim Tracy, an allergist and associate professor at the University of Nebraska, said black boxes would create “obstacles to care,” and that patients could “all of a sudden get terrified. And they, without supervision, they just stop their drug.”

Committee member James McGough, a child psychiatrist at UCLA, concurred, recalling the FDA’s 2004 addition of black box warnings for child and adolescent suicide on SSRIs and which, in his opinion, backfired. “There’s a clear association between declining antidepressant use and increased suicide among youth,” he said.

It is noteworthy that while industry fought and continues to fight SSRI black boxes, both their use and the suicide rate have never been higher. U.S. suicide is 33 percent higher than it was two decades ago, and one in eight Americans is on antidepressants. Declining prescriptions of antidepressants clearly aren’t causal.

Patient safety or profit safety?

Sadly, when warnings could affect drug sales, there is often a battle. When the huge Salmeterol Multi-center Asthma Research Trial, or SMART trial was terminated in 2003 after 16 deaths, 44 intubations, and 369 hospitalizations, mostly in African-Americans, black boxes were added to Advair and Serevent which contain salmeterol and to Symbicort, Dulera and Foradil which contain the similar, formoterol fumarate. The drugs are known as long-acting beta-agonists or LABAs.

The industry assailed the warnings as it did SSRI black boxes, citing the National Asthma Education and Prevention Program Expert Panel Report 3 as proof of LABA safety though it was written almost exclusively by industry-funded physicians. For example, William W. Busse, MD, who chaired the expert panel, listed 21 relationships with drug makers.

But there were other safety signals, especially concerning Glaxo’s Advair. According to ProPublica, in 2011, the Justice Department said Glaxo’s Advair promotion had exposed patients to “significant safety risks,” and there were “scores of lawsuits” from people “whose relatives have died while taking Advair.”

Nevertheless, the FDA asked Glaxo and other LABA makers, AstraZeneca, Novartis, and Merck in 2011 to conduct studies on LABA safety despite objectivity questions and the cloud over Glaxo. In 2017 the FDA repealed the LABA black boxes on the basis of the industry studies. William Busse led the analysis.

Is montelukast so safe it needs no black box? Are LABAs so safe their black box can be removed? Unfortunately, black boxes are too frequently regarded by the influential drug industry as profit warnings, not health warnings.

Martha Rosenberg is a health reporter and the author of Born With a Junk Food Deficiency.  

Image credit: Shutterstock.com 

Prev

The primary care solution is obvious, but don’t expect policymakers to jump on board

January 31, 2020 Kevin 7
…
Next

Black Man Syndrome: in memory of Bryce Gowdy

February 1, 2020 Kevin 0
…

Tagged as: Medications, Pulmonology

Post navigation

< Previous Post
The primary care solution is obvious, but don’t expect policymakers to jump on board
Next Post >
Black Man Syndrome: in memory of Bryce Gowdy

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

More by Martha Rosenberg

  • Conflicts of interest are eroding trust in U.S. health agencies

    Martha Rosenberg
  • How drug companies turned “depression” into a billion-dollar industry

    Martha Rosenberg
  • The untold truths behind overdiagnosis and why it matters to your health

    Martha Rosenberg

Related Posts

  • Are negative news cycles and social media injurious to our health?

    Rabia Jalal, MD
  • Protecting Black women’s maternal health is urgent

    Cessilye R. Smith
  • How social media can help or hurt your health care career

    Health eCareers
  • Sharing mental health issues on social media

    Tarena Lofton
  • Black health care professionals are in mourning and deserve to be entirely heard

    Ellelan Degife
  • It takes more than marching to make Black lives matter in health care

    Torie S. Sepah, MD

More in Meds

  • A world without antidepressants: What could possibly go wrong?

    Tomi Mitchell, MD
  • The truth about GLP-1 medications for weight loss: What every patient should know

    Nisha Kuruvadi, DO
  • The hidden bias in how we treat chronic pain

    Richard A. Lawhern, PhD
  • Biologics are not small molecules: the case for pre-allergy testing in an era of immune-based therapies

    Robert Trent
  • The anesthesia spectrum: Guiding patients through comfort options in oral surgery

    Dexter Mattox, MD, DMD
  • Functional precision oncology: a game changer in cancer therapy

    Chris Apfel, MD, PhD, MBA
  • Most Popular

  • Past Week

    • What’s driving medical students away from primary care?

      ​​Vineeth Amba, MPH, Archita Goyal, and Wayne Altman, MD | Education
    • A faster path to becoming a doctor is possible—here’s how

      Ankit Jain | Education
    • Why no medical malpractice firm responded to my scientific protocol

      Howard Smith, MD | Physician
    • A world without antidepressants: What could possibly go wrong?

      Tomi Mitchell, MD | Meds
    • Why funding cuts to academic medical centers impact all of us [PODCAST]

      The Podcast by KevinMD | Podcast
    • Bridging the digital divide: Addressing health inequities through home-based AI solutions

      Dr. Sreeram Mullankandy | Tech
  • Past 6 Months

    • Internal Medicine 2025: inspiration at the annual meeting

      American College of Physicians | Physician
    • The silent crisis hurting pain patients and their doctors

      Kayvan Haddadan, MD | Physician
    • What’s driving medical students away from primary care?

      ​​Vineeth Amba, MPH, Archita Goyal, and Wayne Altman, MD | Education
    • What happened to real care in health care?

      Christopher H. Foster, PhD, MPA | Policy
    • Are quotas a solution to physician shortages?

      Jacob Murphy | Education
    • How to build a culture where physicians feel valued [PODCAST]

      The Podcast by KevinMD | Podcast
  • Recent Posts

    • Why funding cuts to academic medical centers impact all of us [PODCAST]

      The Podcast by KevinMD | Podcast
    • What’s driving medical students away from primary care?

      ​​Vineeth Amba, MPH, Archita Goyal, and Wayne Altman, MD | Education
    • When rock bottom is a turning point: Why the turmoil at HHS may be a blessing in disguise

      Muhamad Aly Rifai, MD | Physician
    • How grief transformed a psychiatrist’s approach to patient care

      Devina Maya Wadhwa, MD | Physician
    • A speech pathologist’s key to better, safer patient care

      Adena Dacy, CCC-SLP | Conditions
    • Navigating physician non-competes: a strategy for staying put [PODCAST]

      The Podcast by KevinMD | Podcast

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 21 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

  • Most Popular

  • Past Week

    • What’s driving medical students away from primary care?

      ​​Vineeth Amba, MPH, Archita Goyal, and Wayne Altman, MD | Education
    • A faster path to becoming a doctor is possible—here’s how

      Ankit Jain | Education
    • Why no medical malpractice firm responded to my scientific protocol

      Howard Smith, MD | Physician
    • A world without antidepressants: What could possibly go wrong?

      Tomi Mitchell, MD | Meds
    • Why funding cuts to academic medical centers impact all of us [PODCAST]

      The Podcast by KevinMD | Podcast
    • Bridging the digital divide: Addressing health inequities through home-based AI solutions

      Dr. Sreeram Mullankandy | Tech
  • Past 6 Months

    • Internal Medicine 2025: inspiration at the annual meeting

      American College of Physicians | Physician
    • The silent crisis hurting pain patients and their doctors

      Kayvan Haddadan, MD | Physician
    • What’s driving medical students away from primary care?

      ​​Vineeth Amba, MPH, Archita Goyal, and Wayne Altman, MD | Education
    • What happened to real care in health care?

      Christopher H. Foster, PhD, MPA | Policy
    • Are quotas a solution to physician shortages?

      Jacob Murphy | Education
    • How to build a culture where physicians feel valued [PODCAST]

      The Podcast by KevinMD | Podcast
  • Recent Posts

    • Why funding cuts to academic medical centers impact all of us [PODCAST]

      The Podcast by KevinMD | Podcast
    • What’s driving medical students away from primary care?

      ​​Vineeth Amba, MPH, Archita Goyal, and Wayne Altman, MD | Education
    • When rock bottom is a turning point: Why the turmoil at HHS may be a blessing in disguise

      Muhamad Aly Rifai, MD | Physician
    • How grief transformed a psychiatrist’s approach to patient care

      Devina Maya Wadhwa, MD | Physician
    • A speech pathologist’s key to better, safer patient care

      Adena Dacy, CCC-SLP | Conditions
    • Navigating physician non-competes: a strategy for staying put [PODCAST]

      The Podcast by KevinMD | Podcast

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Black boxes: health warning or profit warning?
21 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...